Adoptive immunotherapy against sarcomas

Giulia Mesiano, Valeria Leuci, Lidia Giraudo, Loretta Gammaitoni, Fabrizio Carnevale Schianca, Michela Cangemi, Ramona Rotolo, Sonia Capellero, Ymera Pignochino, Giovanni Grignani, Massimo Aglietta, Dario Sangiolo

Research output: Contribution to journalArticle

Abstract

Introduction: Conventional treatments reached an unsatisfactory therapeutic plateau in the treatment of advanced unresectable bone and soft tissue sarcomas that remain an unsolved medical need. Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas.Areas covered: In this work we reviewed adoptive immunotherapy strategies that have been explored in sarcoma settings, with specific focus on issues related to their clinic transferability. We schematically divided approaches based on T lymphocytes specific for MHC-restricted tumor-associated antigens or relying on MHC-independent immune effectors such as natural killer (NK), cytokine-induced killer (CIK) or γδ T cells.Expert opinion: Preclinical findings and initial clinical reports showed the potentialities and drawbacks of different adoptive immunotherapy strategies. The expansion of tumor infiltrating lymphocytes is difficult to be reproduced outside melanoma. Genetically redirected T cells appear to be a promising option and initial reports are encouraging against patients with sarcomas. Adoptive immunotherapy with MHC-unrestricted effectors such as NK, CIK or γδ T cells has recently shown great preclinical potential in sarcoma setting and biologic features that may favor clinical transferability. Combination of different immunotherapy approaches and integration with conventional treatments appear to be key issues for successful designing of next clinical trials.

Original languageEnglish
Pages (from-to)517-528
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume15
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Keywords

  • Adoptive immunotherapy
  • Cytokine-induced killer cells
  • Natural killer cells
  • Sarcomas

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Adoptive immunotherapy against sarcomas'. Together they form a unique fingerprint.

  • Cite this